Osteoporosis and rheumatic diseases

Submitted: 28 July 2014
Accepted: 28 July 2014
Published: 28 June 2014
Abstract Views: 5143
PDF: 3058
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.


Numerous rheumatic diseases, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus, systemic sclerosis, dermatomyositis/polymyositis and vasculitis are characterized by osteoporosis and fragility fractures. Inflammatory cytokines, glucocorticoid treatment, immobilization and reduced physical activity due to painful joints and muscle weakness are considered the main risk factors that cause low body mass density values in these diseases. Emerging evidence highlights the role of inflammatory cytokines, such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, IL-6, IL-7 and IL-17, in the regulation of the bone homeostasis. In fact, chronic inflammation is often characterized by an imbalance between bone formation and bone resorption with a net prevalence of osteoclastogenesis, which is an important determinant of bone loss in rheumatic diseases.



PlumX Metrics


Download data is not yet available.


How to Cite

Maruotti, N., Corrado, A., & Cantatore, F. (2014). Osteoporosis and rheumatic diseases. Reumatismo, 66(2), 125–135. https://doi.org/10.4081/reumatismo.2014.785

Similar Articles

You may also start an advanced similarity search for this article.